John David Norris

Molecular pharmacology of the nucler receptor class of transcription factors. Special interest in the mode of action of tissue specific ligands for the estrogen and androgen receptors.

Current Appointments & Affiliations

Associate Research Professor of Pharmacology and Cancer Biology · 2012 - Present Pharmacology & Cancer Biology, Basic Science Departments

Recent Publications

Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.

Journal Article Clin Cancer Res · January 6, 2026 PURPOSE: BMS-986365, a heterobifunctional androgen receptor (AR) ligand-directed degrader, was designed as a potent cereblon-dependent degrader and competitive antagonist of the AR to overcome resistance to AR pathway inhibition (ARPI) in metastatic prosta ... Full text Link to item Cite

7993 Thienopyrimidine-Based Estrogen Receptor Modulators Adopt Unique Ligand Binding Poses to Elicit Anti-Proliferative Activities in ER+ Breast Cancer Cells

Conference Journal of the Endocrine Society · October 5, 2024 AbstractDisclosure: E.C. Fink: None. S.L. Mateus: None. N. Meganathan: None. V.K. Sammeta: None. J.D. Norris: None. D.P. McDonnell: None. T. Willson: None. S.W. Fanning: None. Full text Cite

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.

Journal Article Nat Commun · September 3, 2024 Most prostate cancers express the androgen receptor (AR), and tumor growth and progression are facilitated by exceptionally low levels of systemic or intratumorally produced androgens. Thus, absolute inhibition of the androgen signaling axis remains the go ... Full text Link to item Cite

View All Publications

Education, Training & Certifications

National University of Ireland (Ireland) · 1998 Ph.D.

John David Norris

Overview

Current Appointments & Affiliations

Recent Publications

Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.

7993 Thienopyrimidine-Based Estrogen Receptor Modulators Adopt Unique Ligand Binding Poses to Elicit Anti-Proliferative Activities in ER+ Breast Cancer Cells

Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.

Recent Grants

Manipulating normal estrogen physiology as a therapeutic approach in cancer

Elucidation of the mechanisms by which cells recognize and respond to different levels of androgens

HOXB13 as a therapeutic target in prostate cancer

Education, Training & Certifications